Optimization of naphthyridones into selective TATA-binding protein associated factor 1 (TAF1) bromodomain inhibitors

Michael A. Clegg, Natalie H. Theodoulou, Paul Bamborough, Chun-wa Chung, Peter D. Craggs, Emmanuel H. Demont, Laurie J. Gordon, Gemma M. Liwicki, Alex Phillipou, Nicholas C. O. Tomkinson, Rab K. Prinjha, Philip G. Humphreys

Research output: Contribution to journalArticlepeer-review

Abstract

Bromodomain containing proteins and the acetyl-lysine binding bromodomains contained therein are increasingly attractive targets for the development of novel epigenetic therapeutics. To help validate this target class and unravel the complex associated biology, there has been a concerted effort to develop selective small molecule bromodomain inhibitors. Herein we describe the structure-based efforts and multiple challenges encountered in optimizing a naphthyridone template into selective TAF1(2) bromodomain inhibitors which, while unsuitable as chemical probes themselves, show promise for the future development of small molecules to interrogate TAF1(2) biology. Key to this work was the introduction and modulation of the basicity of a pendant amine which had a substantial impact on not only bromodomain selectivity but also cellular target engagement.

Original languageEnglish
Pages (from-to)1308-1317
Number of pages10
JournalACS Medicinal Chemistry Letters
Volume12
Issue number8
Early online date3 Aug 2021
DOIs
Publication statusPublished - 12 Aug 2021

Keywords

  • bromodomain
  • epigenetics
  • TAF1
  • TAF1L

Fingerprint

Dive into the research topics of 'Optimization of naphthyridones into selective TATA-binding protein associated factor 1 (TAF1) bromodomain inhibitors'. Together they form a unique fingerprint.

Cite this